Physician profile
Mark B Lampert
NPI 1023104247
$7,104.51
in general payments reported to CMS, 2019-2025
11 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,765 · 2021: $1,142 · 2022: $1,279 · 2023: $96.87 · 2024: $754 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $960 · Consulting Fee: $720 · Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $960.00 |
| Consulting Fee | $720.00 |
| Food and Beverage | $237.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $2,972.50 | 2020-2021 | |
| Baxter Healthcare | $2,910.00 | 2022-2025 | |
| Abbott Laboratories | $895.33 | 2020-2021 | |
| Novo Nordisk INC | $96.87 | 2023 | |
| Philips North America LLC | $49.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.22 | 2021-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.51 | 2024 | Jardiance |
| Pfizer INC. | $32.29 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.49 | 2025 | |
| Janssen Pharmaceuticals, INC | $24.20 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.99 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lampert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.